🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Reyataz®

Found 38 matching trials

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

PHASE3

The objective of this study is to evaluate the safety and efficacy of a reg...

Status

Completed

Location

University of Alabama at Birmingham

Start Date

2010-04

Trial ID

NCT01108510

Treatments Being Tested

COBI RTV ATV FTC/TDF COBI placebo RTV placebo

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

PHASE4

The goal of this clinical study is to provide continued access to the study...

Status

Recruiting

Location

Helios Salud

Start Date

2024-08-27

Trial ID

NCT06337032

Pharmacokinetics, Safety & Tolerability of Isotopologs of Atazanavir (ATV), With Pharmacokinetic Comparison to Reyataz

PHASE1

The purpose of this study is to assess the safety, tolerability and pharmac...

Status

Completed

Location

Multiple Locations

Start Date

2010-12

Trial ID

NCT01458769

Treatments Being Tested

C-10276 C-10276 C-10297 C-10299 C-10297 C-10299 C-10276 Reyataz®

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

PHASE3

The primary objective of this study is to evaluate the efficacy of switchin...

Status

Completed

Location

University of Alabama at Birmingham

Start Date

2018-08-28

Trial ID

NCT03631732

Treatments Being Tested

B/F/TAF NRTIs Third Agent

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

PHASE3

The primary objective of this study is to evaluate the efficacy of tenofovi...

Status

Completed

Location

Midway Immunology and Research center

Start Date

2013-10-25

Trial ID

NCT01967940

Treatments Being Tested

TAF Placebo E/C/F/TAF Current failing ARV regimen ATV

Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults

PHASE4

The primary objective of this study is to assess glomerular function before...

Status

Completed

Location

Multiple Locations

Start Date

2014-12-15

Trial ID

NCT02246998

Treatments Being Tested

STB TVD ATR RTV ATV ABC/3TC Iohexol

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

PHASE3

The purpose of this randomized, open-label, multicenter, active-controlled ...

Status

Completed

Location

University of Alabama - Birmingham

Start Date

2010-11

Trial ID

NCT01252940

Treatments Being Tested

FTC/RPV/TDF PI RTV NRTIs

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

PHASE3

This study will evaluate the efficacy of switching from emtricitabine/tenof...

Status

Completed

Location

University of Alabama at Birmingham

Start Date

2014-05-06

Trial ID

NCT02121795

Treatments Being Tested

FTC/TDF F/TAF Allowed third antiretroviral agent FTC/TDF Placebo F/TAF Placebo

Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)

PHASE2

Vicriviroc (vye-kri-VYE-rock) is an investigational drug (not yet approved ...

Status

Completed

Location

Multiple Locations

Start Date

2007-12

Trial ID

NCT00551018

Treatments Being Tested

Vicriviroc emtricitabine and tenofovir disoproxil fumarate

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

PHASE2

The goal of this clinical study is to learn more about the safety and dosin...

Status

Active Not Recruiting

Location

Pediatric Infectious Disease Associates

Start Date

2014-01-16

Trial ID

NCT02016924

Treatments Being Tested

ATV DRV Cobicistat BR F/TAF LPV/r Third Unboosted Drug Cobicistat TOS F/TAF TOS

Previous Next